GIS Spinout PathGen Dx to Seek FDA Clearance for Chip-Based Test that Can Detect 70K Pathogens | GenomeWeb

SINGAPORE— Just over a year after beginning operations, PathGen Dx is moving forward with the commercialization of an assay for infectious disease testing.

The assay, which combines a single PCR amplification with an approximately 170,000-probe array, can identify some 70,000 viral and bacterial pathogens, including many that cannot be detected using other commercial multiplexed pathogen-detection assays, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

Sponsored by
Agilent Technologies

This online seminar will discuss a metagenomic assay to identify viruses and other pathogenic microorganisms in human tumor samples, with the aim of gaining a more comprehensive understanding of the role of the microbiome in cancer development and treatment.